{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T09:24:33Z","timestamp":1791883473137,"version":"4.3.4"},"reference-count":0,"publisher":"California Digital Library (CDL)","issue":"6","license":[{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Western Journal of Emergency Medicine"],"abstract":"<p>Introduction: As fentanyl has become more readily available, opioid-related morbidity and mortality in the United States has increased dramatically. Preliminary studies suggest that high-af\ufb01nity, partial mu-opioid receptor agonists such as the combination product buprenorphine-naloxone may reduce mortality from overdose and promote remission. With the escalating prevalence of opioid use disorder (OUD), it is essential to evaluate the effectiveness of opioid agonists like buprenorphine-naloxone. This study examines mortality and remission rates for OUD patients prescribed buprenorphine-naloxone to determine the ef\ufb01cacy of this treatment toward these outcomes. Methods: We carried out a retrospective analysis using the US Collaborative Network database in TriNetX, examining de-identi\ufb01ed medical records from nearly 92 million patients across 56 healthcare organizations. The study spanned the years from January 1, 2017\u2013May 13, 2022. Cohort 1 included OUD patients who began buprenorphine-naloxone treatment within one-year post-diagnosis, while Cohort 2, the control group, consisted of OUD patients who were not administered buprenorphine. The study measured mortality and remission rates within a year of the index event, incorporating propensity score matching for age, gender, and race\/ethnicity. Results: Prior to propensity matching, we identi\ufb01ed a total of 221,967 patients with OUD. Following exclusions, 61,656 patients treated with buprenorphine-naloxone showed 34% fewer deaths within one year of diagnosis compared to 159,061 patients who did not receive buprenorphine (2.6% vs 4.0%; relative risk [RR] 0.661; 95% con\ufb01dence interval [CI] 0.627\u20130.698; P &amp;lt; 0.001). The remission rate was approximately 1.9 times higher in the buprenorphine-naloxone group compared to the control group (18.8% vs 10.1%; RR 1.862; 95% CI 1.812\u20131.914; P &amp;lt; 0.001). After propensity matching, the effect on mortality decreased but remained statistically signi\ufb01cant (2.6% vs 3.0%; RR 0.868; 95% CI 0.813\u20130.927; P &amp;lt; 0.001) and the remission rate remained consistent (18.8% vs 10.4%; RR 1.812; 95% CI 1.750\u20131.876; P &amp;lt; 0.001). Number needed to treat for bene\ufb01t was 249 for death and 12 for remission. Conclusion: Buprenorphine-naloxone was associated with signi\ufb01cantly reduced mortality and increased remission rates for patients with opioid use disorder and should be used as a primary treatment. The recognition and implementation of treatment options like buprenorphine-naloxone is vital in alleviating the impact of OUD.<\/p>","DOI":"10.5811\/westjem.18569","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T15:35:29Z","timestamp":1725636929000},"source":"Crossref","is-referenced-by-count":2,"title":["Buprenorphine-Naloxone for Opioid Use Disorder: Reduction in Mortality and Increased Remission"],"prefix":"10.5811","volume":"25","author":[{"given":"Krishna K.","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian G.","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Troung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura vita Q.","family":"Paglicawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn A.","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Preston","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren G.","family":"Bothwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgiy","family":"Golovko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeoshina","family":"Pillay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietrich","family":"Jehle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"29705","published-online":{"date-parts":[[2024,9,6]]},"container-title":["Western Journal of Emergency Medicine"],"original-title":[],"link":[{"URL":"https:\/\/escholarship.org\/content\/qt0f81n173\/qt0f81n173.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T17:44:42Z","timestamp":1732643082000},"score":1,"resource":{"primary":{"URL":"https:\/\/escholarship.org\/uc\/item\/0f81n173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,6]]},"references-count":0,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,11,26]]}},"URL":"https:\/\/doi.org\/10.5811\/westjem.18569","relation":{},"ISSN":["1936-9018"],"issn-type":[{"value":"1936-9018","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,6]]}}}